CN103069276A - Hmgb1作为炎性肠病病情的生物标志物的用途、其在粪便样品中的非侵入性检测方法及其试剂盒 - Google Patents

Hmgb1作为炎性肠病病情的生物标志物的用途、其在粪便样品中的非侵入性检测方法及其试剂盒 Download PDF

Info

Publication number
CN103069276A
CN103069276A CN2011800327624A CN201180032762A CN103069276A CN 103069276 A CN103069276 A CN 103069276A CN 2011800327624 A CN2011800327624 A CN 2011800327624A CN 201180032762 A CN201180032762 A CN 201180032762A CN 103069276 A CN103069276 A CN 103069276A
Authority
CN
China
Prior art keywords
hmgb1
antibody
disease
aforementioned
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800327624A
Other languages
English (en)
Chinese (zh)
Inventor
S·卡西亚拉
L·斯特纳蒂
R·维塔里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DMG Italia SRL
Original Assignee
DMG Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DMG Italia SRL filed Critical DMG Italia SRL
Publication of CN103069276A publication Critical patent/CN103069276A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2011800327624A 2010-08-05 2011-08-01 Hmgb1作为炎性肠病病情的生物标志物的用途、其在粪便样品中的非侵入性检测方法及其试剂盒 Pending CN103069276A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2010A000442A IT1406051B1 (it) 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
IT2010A000442 2010-08-05
PCT/IT2011/000276 WO2012017466A1 (en) 2010-08-05 2011-08-01 Use of hmgb1 as' a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof

Publications (1)

Publication Number Publication Date
CN103069276A true CN103069276A (zh) 2013-04-24

Family

ID=43739596

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800327624A Pending CN103069276A (zh) 2010-08-05 2011-08-01 Hmgb1作为炎性肠病病情的生物标志物的用途、其在粪便样品中的非侵入性检测方法及其试剂盒

Country Status (14)

Country Link
US (1) US20130137123A1 (enExample)
EP (1) EP2601525A1 (enExample)
JP (1) JP2013534313A (enExample)
CN (1) CN103069276A (enExample)
AU (1) AU2011287193B2 (enExample)
BR (1) BR112013002145A2 (enExample)
CA (1) CA2807107C (enExample)
CL (1) CL2013000223A1 (enExample)
EA (1) EA201390197A1 (enExample)
IL (1) IL223845A (enExample)
IT (1) IT1406051B1 (enExample)
MX (1) MX2013001327A (enExample)
PE (1) PE20131062A1 (enExample)
WO (1) WO2012017466A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
PL2968443T3 (pl) 2013-03-15 2022-02-07 Protagonist Therapeutics, Inc. Analogi hepcydyny i ich zastosowania
CN113621027A (zh) 2014-05-16 2021-11-09 领导医疗有限公司 α4β7整联蛋白硫醚肽拮抗剂
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
HUE062498T2 (hu) 2017-05-12 2023-11-28 Evonik Operations Gmbh Eljárás madárállományban C. perfringens által kiváltott betegségek kimutatására
IT201700083044A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
IT201700083055A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MX2020009044A (es) 2018-03-02 2020-10-12 Evonik Operations Gmbh Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales.
CN109030817A (zh) * 2018-07-04 2018-12-18 长沙都正医学检验有限责任公司 Hmgb1检测试剂盒及其制备方法
US12449424B2 (en) 2018-12-14 2025-10-21 Evonik Operations Gmbh In vitro method for detecting avian intestinal dysbiosis
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
EP4090669A4 (en) 2020-01-15 2024-11-20 Janssen Biotech, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES
CN118063554A (zh) 2020-01-15 2024-05-24 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
EP4247403A4 (en) 2020-11-20 2024-12-11 JANSSEN Pharmaceutica NV COMPOSITIONS OF PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR
AU2022311814A1 (en) 2021-07-14 2024-02-29 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
CN116973572B (zh) * 2023-06-02 2025-03-07 东南大学附属中大医院 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US20060188883A1 (en) * 2003-03-08 2006-08-24 Murray Graeme I Markers for colorectal cancer
CN101132811A (zh) * 2004-10-22 2008-02-27 米迪缪尼股份有限公司 抗hmgb1的高亲和力抗体及其用法
WO2009017444A2 (en) * 2007-08-02 2009-02-05 Iss Immune System Stimulation Ab Diagnosis, staging and monitoring of inflammatory bowel disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2262443A1 (en) * 1996-07-17 1998-01-22 Kaneka Corporation Diagnostic drugs for autoimmune diseases
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
JP5382570B2 (ja) * 2006-12-20 2014-01-08 株式会社シノテスト ヒトｈｍｇｂ１と特異的に結合する鳥類由来の抗体、ヒトｈｍｇｂ１の免疫学的測定方法及びヒトｈｍｇｂ１の免疫学的測定試薬
KR20100124326A (ko) * 2008-03-14 2010-11-26 엑사젠 다이어그노스틱스, 인코포레이티드 염증성 장 질병 및 과민성 장 증후군에 대한 생체마커

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US20060188883A1 (en) * 2003-03-08 2006-08-24 Murray Graeme I Markers for colorectal cancer
CN101132811A (zh) * 2004-10-22 2008-02-27 米迪缪尼股份有限公司 抗hmgb1的高亲和力抗体及其用法
WO2009017444A2 (en) * 2007-08-02 2009-02-05 Iss Immune System Stimulation Ab Diagnosis, staging and monitoring of inflammatory bowel disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RYAN M. LEVY ET AL.: "Systemic inflammation and remote organ injury following trauma require HMGB1", 《AM J PHYSIOL REGUL INTEGR COMP PHYSIOL》, vol. 293, 1 October 2007 (2007-10-01), pages 1538 - 1544 *

Also Published As

Publication number Publication date
ITRM20100442A1 (it) 2012-02-06
IL223845A (en) 2016-06-30
BR112013002145A2 (pt) 2016-05-24
AU2011287193A1 (en) 2013-06-13
CL2013000223A1 (es) 2014-03-28
JP2013534313A (ja) 2013-09-02
EP2601525A1 (en) 2013-06-12
PE20131062A1 (es) 2013-10-16
IT1406051B1 (it) 2014-02-06
US20130137123A1 (en) 2013-05-30
MX2013001327A (es) 2013-03-08
WO2012017466A1 (en) 2012-02-09
CA2807107C (en) 2017-01-03
AU2011287193B2 (en) 2015-08-13
EA201390197A1 (ru) 2013-06-28
WO2012017466A8 (en) 2013-07-11
CA2807107A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
AU2011287193B2 (en) Use of HMGB1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
Roda et al. Crohn’s disease
Zollner et al. Faecal biomarkers in inflammatory bowel diseases: calprotectin versus lipocalin-2—a comparative study
Linsalata et al. Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study
Kaiser et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome
Leach et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease
Carroccio et al. Fecal assays detect hypersensitivity to cow's milk protein and gluten in adults with irritable bowel syndrome
JP2019194600A (ja) 過敏性腸症候群を診断するための経路特異的マーカー
van de Logt et al. S 100 A 12: A noninvasive marker of inflammation in inflammatory bowel disease
Angulo et al. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders
Wędrychowicz et al. Prognostic value of assessment of stool and serum IL-1β, IL-1ra and IL-6 concentrations in children with active and inactive ulcerative colitis
KR20100063052A (ko) 염증성 장 질환의 진단, 단계 구분 및 모니터링 방법
Manolakis et al. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome
Wright et al. Comparison of fecal inflammatory markers in Crohn's disease
Mori et al. Evaluation of serum calprotectin levels in patients with inflammatory bowel disease
Klimczak et al. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity
WO2021151942A1 (en) Test and in vitro diagnosis of irritable bowel syndrome
Giulia et al. Crohn’s disease (Primer)
Toğrol et al. The significance of coeliac disease antibodies in patients with ankylosing spondylitis: a case-controlled study
KR20130136964A (ko) 창자 감염성 병태의 생물학적 마커로서 hmgb1의 용도, 대변 샘플에서 그의 검출을 위한 비침습적 방법 및 키트
US20220214357A1 (en) Method of determining the probability of inflammatory bowel disease in a subject being ulcerative colitis or crohn's disease
TWI614501B (zh) ５-甲氧基色胺酸作為發炎疾病診斷試劑之用途
RU2698709C1 (ru) Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей
Şimşek et al. Fecal S100A12 as a Biomarker in Behcet’s Disease
Karakoyun et al. Serum Fetuin A and Secreted Phosphoprotein 24 as Diagnostic Markers in Inflammatory Bowel Disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130424